Clinicopathological features and EGFR gene mutation status in elderly patients with resected non–small-cell lung cancer

Table 1 Correlations between EGFR mutations and clinicopathological features

Characteristics	Total	No. of patients
		*EGFR*status		p ^a	*KRAS*status		p ^a
		Mutation	Wild-type		Mutation	Wild-type
	(n = 388)	(n = 185, 47.7%)	(n = 203, 52.3%)		(n = 33, 8.5%)	(n = 355, 91.5%)
Mean age, yr ± SD^b	66.6 ± 10.0	65.1 ± 10.3	67.9 ± 9.57	0.462	68.6 ± 9.11	66.4 ± 10.1	0.553
Gender				<0.001			0.552
Male	228	75	153		21	207
Female	160	110	50		12	148
Histological type				<0.001			0.059
Adenocarcinoma	302	183	119		30	272
Others	86	2	84		3	83
Vascular invasion
Ly -	314	155	159	0.172	25	289	0.429
Ly +	74	30	44		8	66
V -	261	151	110	<0.001	23	238	0.756
V +	127	34	93		10	117
p-stage				<0.001
I	293	155	138		22	271	0.217
II / III	95	30	65		11	84
T-factor				<0.001
T1	197	114	83		14	183	0.316
T2 / 3	191	71	120		19	191
Tumor diameter (cm)	3.03 ± 1.43	2.68 ± 0.92	3.35 ± 1.71	<0.001	3.46 ± 1.99	2.99 ± 1.36	0.001
N-factor				0.348
N0	322	157	165		29	293	0.435
N1 / 2	66	28	38		4	62
Smoking status				<0.001			0.107
Non-smoker	157	106	51		9	148
Smoker	231	79	152		24	207
Pre-existing cardiopulmonary comorbidity	203	86	117	0.028	20	183	0.319

^ap < 0.05 statistically significant.
^bSD, standard deviation.
EGFR, epidermal growth factor receptor; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; ND, lymph node dissection.

ISSN: 1471-2407